No Picture
News

Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

NEWTON, Mass. and FLORENCE, Italy, Oct. 31, 2022 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group (“Menarini”), a privately-held, leading international pharmaceutical company,… Click here to view original post… […]

[adinserter block="3"]
No Picture
News

Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer’s Disease at 2022 CTAD Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)– #CTAD2022–Cognito Therapeutics, a clinical-stage company pioneering disease-modifying therapeutic interventions for neurodegenerative diseases, announced today it has been selected to present clinical data from its proprietary gamma sensory stimulation in patients with Alzheimer’s Disease, at the 2022 Clinical Trials in Alzheimer’s Disease (CTAD), held November 29 – December… Click here to view original post… […]

[adinserter block="3"]
No Picture
News

Thermo Fisher Scientific Continues to Execute Proven Capital Deployment Strategy

WALTHAM, Mass.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today provided an update on capital deployment. Throughout the fourth quarter of 2022, Thermo Fisher expects to execute a $1.0 billion share repurchase program, bringing the total capital deployed on buybacks to $3.0 billion… Click here to view original post… […]

No Picture
News

Thermo Fisher Scientific to Acquire The Binding Site Group

WALTHAM, Mass.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has entered into a definitive agreement to acquire The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics, from a shareholder group led by European private equity… Click here to view original post… […]

No Picture
News

Nuvalent Announces Public Offering of Common Stock

CAMBRIDGE, Mass., Oct. 31, 2022 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that it has commenced an underwritten public offering… Click here to view original post… […]

[adinserter block="3"]
No Picture
News

KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)—- $KALV–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced positive phase 1 data for an orally disintegrating tablet (ODT) formulation for its lead compound sebetralstat. Sebetralstat is currently… Click here to view original post… […]